Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2044.202720312035203920432044
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
10 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jan 2041 · High confidence
Also notable
Ends Sep 2042 · High confidence
Lung Biomarkers and Methods of Use Thereof
US 11,664,092
The most cited patent in this portfolio, cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Enhanced Detection and Quantitation of Biomolecules
US 12,504,432
Granted 2025. Too new for citation comparison; protection runs to 2042. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Lung Biomarkers and Methods of Use Thereof (US 11,664,092) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Enhanced Detection and Quantitation of Biomolecules | 2 in force | to Sep 2042 |
| Lung Biomarkers and Methods of Use Thereof | 2 in force | to Jan 2041 |
| Multi-Omic Assessment Using Proteins and Nucleic Acids | 1 in force | to Mar 2042 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,664,092 | Lung Biomarkers and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,087,405 | Methods of Processing a Biofluid Sample In force · High confidence | In force | High confidence | |
| US 12,334,190 | Multi-Omic Assessment Using Proteins and Nucleic Acids In force · Medium confidence | In force | Medium confidence | |
| US 12,007,397 | Enhanced Detection and Quantitation of Biomolecules In force · High confidence | In force | High confidence | |
| US 12,504,432 | Enhanced Detection and Quantitation of Biomolecules In force · High confidence | In force | High confidence | |
| US 12,387,508 | Direct Classification of Raw Biomolecule Measurement Data In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 10 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed